NCT00150449已完成3 期
A 1-Year Open-Label Safety Extension Study of Pregabalin in Patients With Anxiety Disorders
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 511
- 试验地点
- 138
- 主要终点
- Safety Tolerability
研究概览
简要总结
Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have completed the double-blind portion of the preceding trial
- •Completed any protocol specified withdrawal phase and follow-up visits.
排除标准
- •Patient cannot participate if they experienced a serious adverse event or a nonserious, but medically significant adverse event during the preceding efficacy study that was judged to be related to the study medication.
结局指标
主要结局
Safety Tolerability
次要结局
未报告次要终点
研究者
研究点 (138)
Loading locations...
相似试验
已完成
3 期
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral NeuropathyDiabetic Neuropathy, PainfulNCT00553280Pfizer's Upjohn has merged with Mylan to form Viatris Inc.123
已完成
3 期
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With FibromyalgiaFibromyalgiaNCT00830128Pfizer's Upjohn has merged with Mylan to form Viatris Inc.106
已完成
3 期
An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic PainSpinal Cord DiseasesSpinal Cord InjuriesNeuralgiaPainNCT01202227Pfizer's Upjohn has merged with Mylan to form Viatris Inc.104
已完成
2 期
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.Epilepsy, PartialNCT00141414Pfizer82
已完成
3 期
Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.PainNCT00141362Pfizer325